U.S., May 14 -- ClinicalTrials.gov registry received information related to the study (NCT07584369) titled 'Short-term Effects of Methamphetamine on Residual Latent HIV Disease Study' on April 13.
Brief Summary: The most commonly used illicit stimulant in people with HIV (PWH) is methamphetamine (MA). Prior studies demonstrate strong evidence that MA promotes increased HIV transcription as well as immune dysregulation. A challenge in achieving worldwide HIV eradication is targeting specific marginalized populations who are most likely to benefit from an HIV cure but possess poorer immune responses. For this study, N = ~20 PWH virally-suppressed on antiretroviral therapy (ART) with no prior history of MA use disorder will be administered or...